Healthcare - Biotechnology - NASDAQ - US
$ 0.519
-12.1 %
$ 32.1 M
Market Cap
-0.38
P/E
CASH FLOW STATEMENT
-78.3 M
OPERATING CASH FLOW
65.2 M
INVESTING CASH FLOW
135 K
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Passage Bio, Inc.
| Net Income | -102 M |
| Depreciation & Amortization | 3.72 M |
| Capital Expenditures | -146 K |
| Stock-Based Compensation | 10.9 M |
| Change in Working Capital | 5.34 M |
| Others | 11.9 M |
| Free Cash Flow | -78.4 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (102.1) | (136.1) | (185.4) | (112.2) | (45.6) | (12.8) |
| Depreciation & Amortization | 3.7 | 3.7 | 1.5 | 0.8 | 0.1 | 0 |
| Deferred Income Tax | 0 | 0 | 2.8 | 0.6 | 9.1 | 0 |
| Stock Based Compensation | 10.9 | 19.0 | 32.7 | 14.6 | 1.5 | 0 |
| Other Operating Activities | 3.8 | 3.8 | 10.1 | 1.3 | 1.0 | 2.7 |
| Change in Working Capital | 5.3 | (8.5) | 11.4 | 14.4 | (5.9) | (8.5) |
| Cash From Operations | (78.3) | (118.2) | (126.9) | (80.5) | (39.9) | (18.6) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (0.1) | (5.3) | (25.6) | (1.6) | (1.7) | (2.5) |
| Other Items | 65.4 | 30.5 | (20.2) | (170.5) | 0 | 0 |
| Cash From Investing Activities | 65.2 | 25.2 | (45.8) | (172.1) | (1.7) | (2.5) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (1.4) | 37 K | 0.3 | 175.6 | 46.0 |
| Cash From Financing Activities | 0.1 | 1.35 K | 0.2 | 228.8 | 175.6 | 46.0 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (12.9) | (94.4) | (6.0) | (23.9) | 134.0 | 24.9 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (78.4) | (123.5) | (152.5) | (82.2) | (41.6) | (21.1) |